XFOR on XNAS, Health Care, X4 Pharmaceuticals, Inc., job postings
Measures activity, not value. Not investment advice.
Revenue fell 50% to $17M while short interest reached 4.4 times its year-earlier level.
BadNet loss $80.5M over 12 months, while cash $187.7M exceeds $75M debt
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Industry
Biological products, (no diagnostic substances) (Health Care)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $2.9M, net loss $20.2M.
31 Dec 2021RevenueNet incomeNet losstallest bar $90.8M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$2.9M
-$20.2M
30 Jun 2026
$8.8M
-$16.2M
31 Mar 2026
$2.7M
-$20.2M
31 Dec 2025
$2.6M
-$23.9M
30 Sep 2025
$1.8M
-$29.8M
30 Jun 2025
$2.0M
-$25.7M
31 Mar 2025
$28.8M
$282K
31 Dec 2024
$1.4M
-$39.8M
30 Sep 2024
$560K
-$36.7M
30 Jun 2024
$700K
$90.8M
31 Mar 2024
$0
-$51.8M
31 Dec 2023
–
-$19.1M
30 Sep 2023
$0
-$2.3M
30 Jun 2023
$0
-$55.7M
31 Mar 2023
–
-$24.0M
31 Dec 2022
–
-$29.1M
30 Sep 2022
–
-$21.6M
30 Jun 2022
–
-$21.2M
31 Mar 2022
–
-$22.0M
31 Dec 2021
$0
-$30.2M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$17.0M
$34.0M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-50%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$80.5M
-$95.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
81.8%
83.2%
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-474%
-291%
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-475%
-280%
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-80.3%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
-$103.1M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$187.7M
$122.2M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$75.0M
$75.0M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$112.7M (net cash)
-$47.2M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.54
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$1.36
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
18.1
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
11.4
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
2.2
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$22K
bought $12K, sold $34K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+6.8%
94 13F filers vs 88
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
108.1M shares held by 13F filers (30 Sep 2026) of 102.1M outstanding (2 Nov 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
7.8%
8.0M shares sold short (30 Oct 2026) of 102.1M outstanding (2 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
10.9
8.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+6.5%
7.5M shares sold short in the report before, 8.0M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
39%
39% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 50%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
2
Tracked since 21 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 21 Nov 2026; the change shows after 30 days.
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
7
7 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
7 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 8.2M, 4.4× a year earlier
Price $3.00 on 20 Nov 2026, -19% over 12 months (12-month range $2.45 to $4.67)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $451K in the last 12 months (the 12 months before: $175K).Revenue per quarter. Revenue $2.9M in the latest quarter, +63% on a year earlier.Capital spending per quarter. Capital spending $0 in the latest quarter.Institutional holders (13F filers). 94 13F filers reported holding it in the latest 13F quarter, +141% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $0; public on 18 Mar 2022
Quarter ended 30 Jun 2023: $0; public on 9 Aug 2024
Quarter ended 30 Sep 2023: $0; public on 14 Nov 2024
Quarter ended 31 Mar 2024: $0; public on 2 May 2025
Quarter ended 30 Jun 2024: $700K; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $560K; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $1.4M; public on 27 Mar 2025
Quarter ended 31 Mar 2025: $28.8M; public on 2 May 2025
Quarter ended 30 Jun 2025: $2.0M, +182% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $1.8M, +215% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $2.6M, +79% on a year earlier; public on 18 Mar 2026
Quarter ended 31 Mar 2026: $2.7M, -91% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $8.8M, +346% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $2.9M, +63% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $13K; public on 18 Mar 2022
Quarter ended 31 Mar 2022: $22K, -96% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $38K, -56% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $9K, -55% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $34K, +162% on a year earlier; public on 22 Mar 2023
Quarter ended 31 Mar 2023: $9K, -59% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $8K, -79% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $8K, -11% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $35K, +2.9% on a year earlier; public on 22 Mar 2024
Quarter ended 31 Mar 2024: $59K, +556% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $134K, +1575% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $92K, +1050% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $0, -100% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 18 Mar 2026
Institutional holders (13F filers)
31 Dec 2021 report: 49; public on 14 Feb 2022
31 Mar 2022 report: 50; public on 16 May 2022
30 Jun 2022 report: 49; public on 15 Aug 2022
30 Sep 2022 report: 54; public on 14 Nov 2022
31 Dec 2022 report: 52; public on 14 Feb 2023
31 Mar 2023 report: 56; public on 15 May 2023
30 Jun 2023 report: 91; public on 14 Aug 2023
30 Sep 2023 report: 85; public on 14 Nov 2023
31 Dec 2023 report: 83; public on 14 Feb 2024
31 Mar 2024 report: 94; public on 15 May 2024
30 Jun 2024 report: 96; public on 14 Aug 2024
30 Sep 2024 report: 94; public on 14 Nov 2024
31 Dec 2024 report: 89; public on 14 Feb 2025
31 Mar 2025 report: 92; public on 15 May 2025
30 Jun 2025 report: 49; public on 14 Aug 2025
30 Sep 2025 report: 39; public on 14 Nov 2025
31 Dec 2025 report: 77; public on 17 Feb 2026
31 Mar 2026 report: 83; public on 15 May 2026
30 Jun 2026 report: 88; public on 14 Aug 2026
30 Sep 2026 report: 94; public on 16 Nov 2026
What is unusual now
Made public in the last 90 days: it had 8.2M shares sold short in the 15 Sep 2026 report, 4.4× the same report last year; it also had 7.6M shares sold short in the 30 Sep 2026 report, 3.7× the same report last year. 6 sharp changes in all.
Short interest spike: had 8.2M shares sold short in the 15 Sep 2026 report, 4.4× the same report last year Public on 25 Sep 2026.
Two or more unrelated kinds of records unusual within 30 days
15 Aug 2023confirmed
Confirmed across sources Institutional holdings and Short interest and volume
X4 Pharmaceuticals(XFOR): saw 42 13F filers open a new position in the quarter ended 30 Jun 2023, 10× the same quarter last year, while it had 10.9M shares sold short in the 15 Sep 2023 report, 22× the same report last year. Two unrelated kinds of activity within 105 days.
Short interest and volume: Short interest spike, became public on 13 Jul 2023
Short interest and volume: Short interest spike, became public on 26 Jul 2023
Institutional holdings: Many funds opening a new position, became public on 14 Aug 2023
Short interest and volume: Short interest spike, became public on 10 Aug 2023
Short interest and volume: Short interest spike, became public on 25 Aug 2023
Short interest and volume: Short interest spike, became public on 13 Sep 2023
Short interest and volume: Short interest spike, became public on 27 Sep 2023
Short interest and volume: Short interest spike, became public on 12 Oct 2023
Short interest and volume: Short interest spike, became public on 25 Oct 2023
The quarter ended 30 Jun 2023 against the 8 quarters before it.
this quarterearliernormal: 10See the evidence (9 changes)
Short interest and volume: Short interest spike became public on 13 Jul 2023
X4 Pharmaceuticals had 14.4M shares sold short in the 30 Jun 2023 report, 24× the same report last year.
This period
14.4M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
407K
How far from its usual level
+21.3
Same report last year
597K
History used
1,568 days
the 30 Jun 2023 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jul 2023
X4 Pharmaceuticals had 13.6M shares sold short in the 14 Jul 2023 report, 23× the same report last year.
This period
13.6M (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
407K
How far from its usual level
+19.9
Same report last year
590K
History used
1,582 days
the 14 Jul 2023 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Aug 2023
X4 Pharmaceuticals saw 42 13F filers open a new position in the quarter ended 30 Jun 2023, 10× the same quarter last year.
This period
42 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
10
Typical spread (median absolute deviation)
3.5
How far from its usual level
+6.2
Same quarter last year
4
History used
1,552 days
the quarter ended 30 Jun 20238 earlier quartersnormal: 10
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 10 Aug 2023
X4 Pharmaceuticals had 12.0M shares sold short in the 31 Jul 2023 report, 18× the same report last year.
This period
12.0M (the 31 Jul 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
436K
How far from its usual level
+16.2
Same report last year
671K
History used
1,599 days
the 31 Jul 2023 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Aug 2023
X4 Pharmaceuticals had 11.0M shares sold short in the 15 Aug 2023 report, 8.6× the same report last year.
This period
11.0M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
467K
How far from its usual level
+13.6
Same report last year
1.3M
History used
1,614 days
the 15 Aug 2023 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Sep 2023
X4 Pharmaceuticals had 10.3M shares sold short in the 31 Aug 2023 report, 19× the same report last year.
This period
10.3M (the 31 Aug 2023 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
618K
How far from its usual level
+9.4
Same report last year
549K
History used
1,630 days
the 31 Aug 2023 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Sep 2023
X4 Pharmaceuticals had 10.9M shares sold short in the 15 Sep 2023 report, 22× the same report last year.
This period
10.9M (the 15 Sep 2023 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
700K
How far from its usual level
+8.8
Same report last year
487K
History used
1,645 days
the 15 Sep 2023 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Oct 2023
X4 Pharmaceuticals had 10.6M shares sold short in the 29 Sep 2023 report, 5.9× the same report last year.
This period
10.6M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
792K
How far from its usual level
+7.5
Same report last year
1.8M
History used
1,659 days
the 29 Sep 2023 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Oct 2023
X4 Pharmaceuticals had 10.9M shares sold short in the 13 Oct 2023 report, 6.6× the same report last year.
This period
10.9M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+4.9
Same report last year
1.6M
History used
1,673 days
the 13 Oct 2023 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
11 Nov 2026Short interest and volume change
had 8.0M shares sold short in the 30 Oct 2026 report, 5.3× the same report last year.
Same report last year: 1.5M; its normal report is 3.4M.
See the evidence
This period
8.0M (the 30 Oct 2026 report)
Normal report (median of 24 earlier)
3.4M
Typical spread (median absolute deviation)
628K
How far from its usual level
+4.9
Same report last year
1.5M
History used
2,786 days
the 30 Oct 2026 report24 earlier reportsnormal: 3.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.5M shares sold short in the 15 Oct 2026 report, 4.2× the same report last year.
Same report last year: 1.8M; its normal report is 3.3M.
See the evidence
This period
7.5M (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
561K
How far from its usual level
+5.1
Same report last year
1.8M
History used
2,771 days
the 15 Oct 2026 report24 earlier reportsnormal: 3.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.6M shares sold short in the 30 Sep 2026 report, 3.7× the same report last year.
Same report last year: 2.0M; its normal report is 3.2M.
See the evidence
This period
7.6M (the 30 Sep 2026 report)
Normal report (median of 24 earlier)
3.2M
Typical spread (median absolute deviation)
508K
How far from its usual level
+5.9
Same report last year
2.0M
History used
2,756 days
the 30 Sep 2026 report24 earlier reportsnormal: 3.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.2M shares sold short in the 15 Sep 2026 report, 4.4× the same report last year.
Same report last year: 1.9M; its normal report is 3.1M.
See the evidence
This period
8.2M (the 15 Sep 2026 report)
Normal report (median of 24 earlier)
3.1M
Typical spread (median absolute deviation)
508K
How far from its usual level
+6.8
Same report last year
1.9M
History used
2,741 days
the 15 Sep 2026 report24 earlier reportsnormal: 3.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.2M shares sold short in the 31 Aug 2026 report, 4.6× the same report last year.
Same report last year: 1.6M; its normal report is 3.1M.
See the evidence
This period
7.2M (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
3.1M
Typical spread (median absolute deviation)
508K
How far from its usual level
+5.4
Same report last year
1.6M
History used
2,726 days
the 31 Aug 2026 report24 earlier reportsnormal: 3.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.2M shares sold short in the 14 Aug 2026 report, 2.9× the same report last year.
Same report last year: 2.5M; its normal report is 3.1M.
See the evidence
This period
7.2M (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
3.1M
Typical spread (median absolute deviation)
508K
How far from its usual level
+5.4
Same report last year
2.5M
History used
2,709 days
the 14 Aug 2026 report24 earlier reportsnormal: 3.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.3M shares sold short in the 31 Jul 2026 report, 7.1× the same report last year.
Same report last year: 1.0M; its normal report is 3.1M.
See the evidence
This period
7.3M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
3.1M
Typical spread (median absolute deviation)
508K
How far from its usual level
+5.6
Same report last year
1.0M
History used
2,695 days
the 31 Jul 2026 report24 earlier reportsnormal: 3.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 36 13F filers open a new position in the quarter ended 31 Dec 2025, 3.3× the same quarter last year.
Same quarter last year: 11; its normal quarter is 11.
See the evidence
This period
36 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
11
Typical spread (median absolute deviation)
1.5
How far from its usual level
+8.3
Same quarter last year
11
History used
2,467 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 11
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $28.8M for the quarter ended 31 Mar 2025, against none in the same quarter last year.
See the evidence
This period
$28.8M (the quarter ended 31 Mar 2025)
Normal quarter (median of 6 earlier)
$280K
Typical spread (median absolute deviation)
$280K
How far from its usual level
+28.5
Same quarter last year
$0
History used
2,282 days
the quarter ended 31 Mar 20256 earlier quartersnormal: $280K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 16.5M shares sold short in the 15 Jul 2024 report, 1.2× the same report last year.
Same report last year: 13.6M; its normal report is 12.0M.
See the evidence
This period
16.5M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
12.0M
Typical spread (median absolute deviation)
687K
How far from its usual level
+3.8
Same report last year
13.6M
History used
1,949 days
the 15 Jul 2024 report24 earlier reportsnormal: 12.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.9M shares sold short in the 13 Oct 2023 report, 6.6× the same report last year.
Same report last year: 1.6M; its normal report is 2.4M.
See the evidence
This period
10.9M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+4.9
Same report last year
1.6M
History used
1,673 days
the 13 Oct 2023 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.6M shares sold short in the 29 Sep 2023 report, 5.9× the same report last year.
Same report last year: 1.8M; its normal report is 1.9M.
See the evidence
This period
10.6M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
792K
How far from its usual level
+7.5
Same report last year
1.8M
History used
1,659 days
the 29 Sep 2023 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.9M shares sold short in the 15 Sep 2023 report, 22× the same report last year.
Same report last year: 487K; its normal report is 1.8M.
See the evidence
This period
10.9M (the 15 Sep 2023 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
700K
How far from its usual level
+8.8
Same report last year
487K
History used
1,645 days
the 15 Sep 2023 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.3M shares sold short in the 31 Aug 2023 report, 19× the same report last year.
Same report last year: 549K; its normal report is 1.7M.
See the evidence
This period
10.3M (the 31 Aug 2023 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
618K
How far from its usual level
+9.4
Same report last year
549K
History used
1,630 days
the 31 Aug 2023 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 11.0M shares sold short in the 15 Aug 2023 report, 8.6× the same report last year.
Same report last year: 1.3M; its normal report is 1.6M.
See the evidence
This period
11.0M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
467K
How far from its usual level
+13.6
Same report last year
1.3M
History used
1,614 days
the 15 Aug 2023 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 42 13F filers open a new position in the quarter ended 30 Jun 2023, 10× the same quarter last year, while it had 10.9M shares sold short in the 15 Sep 2023 report, 22× the same report last year. Two unrelated kinds of activity within 105 days.
See the evidence (9 changes)
Short interest and volume: Short interest spike became public on 13 Jul 2023
X4 Pharmaceuticals had 14.4M shares sold short in the 30 Jun 2023 report, 24× the same report last year.
This period
14.4M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
407K
How far from its usual level
+21.3
Same report last year
597K
History used
1,568 days
the 30 Jun 2023 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jul 2023
X4 Pharmaceuticals had 13.6M shares sold short in the 14 Jul 2023 report, 23× the same report last year.
This period
13.6M (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
407K
How far from its usual level
+19.9
Same report last year
590K
History used
1,582 days
the 14 Jul 2023 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Aug 2023
X4 Pharmaceuticals saw 42 13F filers open a new position in the quarter ended 30 Jun 2023, 10× the same quarter last year.
This period
42 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
10
Typical spread (median absolute deviation)
3.5
How far from its usual level
+6.2
Same quarter last year
4
History used
1,552 days
the quarter ended 30 Jun 20238 earlier quartersnormal: 10
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 10 Aug 2023
X4 Pharmaceuticals had 12.0M shares sold short in the 31 Jul 2023 report, 18× the same report last year.
This period
12.0M (the 31 Jul 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
436K
How far from its usual level
+16.2
Same report last year
671K
History used
1,599 days
the 31 Jul 2023 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Aug 2023
X4 Pharmaceuticals had 11.0M shares sold short in the 15 Aug 2023 report, 8.6× the same report last year.
This period
11.0M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
467K
How far from its usual level
+13.6
Same report last year
1.3M
History used
1,614 days
the 15 Aug 2023 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Sep 2023
X4 Pharmaceuticals had 10.3M shares sold short in the 31 Aug 2023 report, 19× the same report last year.
This period
10.3M (the 31 Aug 2023 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
618K
How far from its usual level
+9.4
Same report last year
549K
History used
1,630 days
the 31 Aug 2023 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Sep 2023
X4 Pharmaceuticals had 10.9M shares sold short in the 15 Sep 2023 report, 22× the same report last year.
This period
10.9M (the 15 Sep 2023 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
700K
How far from its usual level
+8.8
Same report last year
487K
History used
1,645 days
the 15 Sep 2023 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Oct 2023
X4 Pharmaceuticals had 10.6M shares sold short in the 29 Sep 2023 report, 5.9× the same report last year.
This period
10.6M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
792K
How far from its usual level
+7.5
Same report last year
1.8M
History used
1,659 days
the 29 Sep 2023 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Oct 2023
X4 Pharmaceuticals had 10.9M shares sold short in the 13 Oct 2023 report, 6.6× the same report last year.
This period
10.9M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+4.9
Same report last year
1.6M
History used
1,673 days
the 13 Oct 2023 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Aug 2023Institutional holdings change
saw 42 13F filers open a new position in the quarter ended 30 Jun 2023, 10× the same quarter last year.
Same quarter last year: 4; its normal quarter is 10.
See the evidence
This period
42 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
10
Typical spread (median absolute deviation)
3.5
How far from its usual level
+6.2
Same quarter last year
4
History used
1,552 days
the quarter ended 30 Jun 20238 earlier quartersnormal: 10
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Showing the newest 40 of 100 entries; narrow the window or the kind of data to see older ones.
Not listed: 247 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001501697
Ticker
XFOR
Domain
x4pharma.com
Employer name
X4 Pharmaceuticals, Inc. (1 unverified)
Hq location
MA|BOSTON|02134 (1 unverified)
Name
Arsanis, Inc., X4 Pharmaceuticals, Inc.
Uei
QFLYNM6J7HW3
DOL H-1B labor condition applications and PERM certifications1 data point8 Aug 2022 to 8 Aug 2022
SEC Form 13F institutional holdings279 data points31 Mar 2019 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)187 records27 Apr 2016 to 4 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)574 data points31 Dec 2015 to 2 Nov 2026
SEC Form 4 insider transactions115 records, 224 data points20 Nov 2017 to 19 Oct 2026
FINRA short interest (twice monthly)549 data points15 Mar 2019 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3868 data points14 Mar 2019 to 20 Nov 2026